Call today to discuss study participation:
1-800-668-4717 in the US
1800-043-212 in AUS 

What to Expect

Participating in ACT-AD

The ACT-AD trial is seeking to enroll approximately up to 75 participants with mild to moderate Alzheimer’s disease in the United States and Australia. Qualified participants will be randomly assigned to receive ATH-1017 or placebo. Participation in the study takes about eight months including approximately six months of treatment duration. During the treatment period, you or your caregiver will administer daily subcutaneous injections using the provided prefilled syringes (i.e. small injection under the skin that you can take at home; the injection is prepared and ready for administration).

circles

Upon completion of the ACT-AD trial, interested participants are eligible to enroll in the Open Label Extension study of ATH-1017. This study ensures participants will receive the active drug.

What is Involved in the Trials?

Call today to discuss study participation:
1-800-668-4717 in the US
1800-043-212 in AUS